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Background: Recent animal studies show a mechanistic link between intestinal microbial metabolism of dietary phosphatidylcholine and coronary 
artery disease (CAD) pathogenesis. Levels of the pro-atherosclerotic metabolite trimethylamine-N-oxide, TMAO, are elevated in patients with diabetes 
mellitus (DM), but their prognostic value remains unclear.
methods: We examined the relationship between fasting plasma TMAO and incident major adverse cardiac events (MACE=death, myocardial 
infarction, stroke) over 3-year follow-up in 4,007 stable subjects undergoing elective coronary angiography.
results: In our study cohort, median TMAO levels were higher in DM (4.4[IQR 2.8-7.7]) versus non-DM (3.5[2.3-5.6], p<0.001). Higher plasma 
TMAO level was associated with a 3-fold increased risk of MACE in DM and a 2.1-fold increased risk of MACE in non-DM. Following adjustments 
for traditional risk factors and hsCRP, elevated TMAO levels remained predictive of MACE risk in both DM (Quartiles 4 vs. 1: Hazard ratio [HR]2.53 
[95%CI 1.66-3.84], p<0.001) and non-DM (HR 1.61 [95%CI 1.15-2.26], p<0.001). There was only modest correlation between TMAO and HbA1c 
(r=0.11; p<0.01).
conclusion: High plasma TMAO levels, a pro-atherogenic compound formed by gut flora dependent metabolism of the choline group of 
phosphatidylcholine, portend stronger incident risk of MACE in both diabetics and non-diabetics alike, with modest relationship to glycemic control.
 
